Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Drug approval process stories

Oct 26, 2026

Bayer wins China approval for stroke prevention drug asundexian

China's drug regulator approved Bayer's blood thinner asundexian for stroke prevention, marking the first approval globally for this new class of anticoagulant. The approval followed a priority review and represents a significant boost for Bayer's pharmaceutical pipeline.

Oct 26, 2026·3 sources
00
Oct 23, 2026

UK approves Johnson & Johnson's oral psoriasis pill for moderate-to-severe plaque psoriasis

Britain's medicines regulator approved Johnson & Johnson's daily pill for adults and teenagers with moderate-to-severe plaque psoriasis, a skin condition causing red, scaly and often itchy patches.

Oct 23, 2026·2 sources
00
Sep 3, 2026

Ultragenyx's Angelman syndrome drug fails Phase 3 trial

Ultragenyx Pharmaceuticals' apazunersen did not meet the goals of its Phase 3 test in Angelman syndrome, a rare genetic neurological disorder with no FDA-approved therapies. The failure of what was once considered a potential blockbuster therapy is forcing Ultragenyx to examine significant cost cuts.

Sep 3, 2026·2 sources
00
Jun 29, 2026

New England Journal of Medicine Retracts Amgen's Tavneos Clinical Trial Amid Data Manipulation Allegations

The New England Journal of Medicine retracted the main clinical trial used to approve Amgen's $500 million drug Tavneos, following allegations of data manipulation. The European Medicines Agency had previously recommended revoking the drug's approval over data integrity concerns.

Jun 29, 2026·1 source
00
May 4, 2026

FDA Rejects Promising Melanoma Drug RP1 Twice, Raising Concerns About Drug Approval Process

The FDA has rejected RP1, a breakthrough melanoma treatment, twice despite its promise in treating skin cancer. The rejections have left medical professionals puzzled and concerned about implications for future drug approvals.

May 4, 2026·1 source
00

Top claims

  • ▪Bristol Myers Squibb and Johnson & Johnson are jointly conducting clinical testing on milvexian, an experimental competitor in the Factor XIa inhibitor drug class
  • ▪The approval of Asundexian by China's National Medical Products Administration followed a priority review designation granted in May 2026 as an accelerated process for urgent medical needs
  • ▪Bayer's broader pharmaceutical pipeline includes newer therapies such as the menopause treatment Lynkuet and the heart treatment Beyonttra

Subtopics

Drug Policy, Pricing & Approval4Drug Approval and Clinical Trials3Clinical evaluation2Clinical Trial Design & Evaluation2Clinical trials2Pharmaceutical Industry2Angelman syndrome1Anticoagulants1Autoimmune disease1Autoimmune disease treatments1Cancer treatment1Cardiovascular diseases1Drug development1Drug safety1FDA drug approval process1Fintech industry1Healthcare Policy1Neurological disorders1New drug application (NDA) process1Pharmaceutical drugs1Scientific misconduct1

Related timelines

Trump administration

161 stories

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Russia-Ukraine war

136 stories